HASAN ÇAĞRI YILDIRIM
Araştırmacı kurumdan ayrılmıştır
Ana Sayfa
Eğitim Bilgileri
Araştırma Alanları
Akademik İdari Deneyim
Yayınlar & Eserler
Proje & Patent & Tasarım
Bilimsel Faaliyetler
Başarılar & Tanınırlık
Duyurular & Dokümanlar
İletişim
Özgeçmiş Dosyası İndir
Türkçe
English
Hacettepe Üniversitesi
Akademik Veri Yönetim Sistemi
English
Akademik Veri Yönetim Sistemi
English
Yayınlar & Eserler
Yayın Ağı
SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım H. Ç.
,
KUTLU Y.
,
Mutlu E.
,
Aykan M. B.
,
Korkmaz M.
,
Yalçın S.
, et al.
International Journal of Clinical Oncology
, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded)
Acute heart failure following pazopanib treatment: a literature review featuring two case reports
KERTMEN N.
,
KAVGACI G.
,
YILDIRIM H. Ç.
,
DİZDAR Ö.
Anti-Cancer Drugs
, cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded)
A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology
YILDIRIM H. Ç.
,
GÜVEN D. C.
,
AKYILDIZ A.
,
YALÇIN Ş.
,
DİZDAR Ö.
Irish Journal of Medical Science
, cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded)
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
Avcı O.
,
İriağaç Y.
,
Çavdar E.
,
Karaboyun K.
,
Araz M.
,
Şakalar T.
, et al.
Journal of Geriatric Oncology
, cilt.14, sa.8, 2023 (SCI-Expanded)
A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer
YILDIRIM H. Ç.
,
Ismayilov R.
,
AKYILDIZ A.
,
GÜVEN D. C.
,
Abdurrahimli N.
,
DİZDAR Ö.
, et al.
Anti-cancer drugs
, cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded)
Advances in the Early Detection of Hepatobiliary Cancers
YILDIRIM H. Ç.
,
KAVGACI G.
,
Chalabiyev E.
,
DİZDAR Ö.
Cancers
, cilt.15, sa.15, 2023 (SCI-Expanded)
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
GÜVEN D. C.
,
ÖZBEK D. A.
,
ŞAHİN T. K.
,
KAVGACI G.
,
Aksun M. S.
,
ERUL E.
, et al.
Anti-Cancer Drugs
, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded)
SMART syndrome: a case report
Bozkurt S.
,
Toprak B.
,
YILDIRIM H. Ç.
,
PARLAK SAĞOL Ş.
,
GÜVEN D. C.
,
KERTMEN N.
, et al.
ACTA NEUROLOGICA BELGICA
, cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded)
Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
AKYILDIZ A.
,
GÜVEN D. C.
,
YILDIRIM H. Ç.
,
Ismayilov R.
,
YILMAZ F.
,
Tatar O. D.
, et al.
Medicine (United States)
, cilt.102, sa.18, 2023 (SCI-Expanded)
The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma
GÜVEN D. C.
,
ERUL E.
,
YILMAZ F.
,
YAŞAR S.
,
YILDIRIM H. Ç.
,
ERCAN F.
, et al.
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded)
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
KUŞ F.
,
Guven D. C.
,
YILDIRIM H. Ç.
,
Chalabiyev E.
,
AKYILDIZ A.
,
Tatar O. D.
, et al.
Biomarkers in Medicine
, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded)
Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C.
,
Incesu F. G. G.
,
YILDIRIM H. Ç.
,
Erul E.
,
Chalabiyev E.
,
AKTAŞ B. Y.
, et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded)
Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey
Kus C.
,
Kus M. M.
,
Keten H. S.
,
Ucer H.
,
Guvenc N.
,
KUŞ F.
, et al.
Children
, cilt.10, sa.2, 2023 (SCI-Expanded)
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
GÜRSOY P.
,
TATLI A. M.
,
Erdem D.
,
GÖKER E.
,
Celik E.
,
Demirci N. S.
, et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.2, ss.865-875, 2023 (SCI-Expanded)
Emerging treatment strategies in hepatobiliary cancer
GÜVEN D. C.
,
YILDIRIM H. Ç.
,
Chalabiyev E.
,
KUŞ F.
,
YILMAZ F.
,
YAŞAR S.
, et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded)
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
Guven D. C.
,
YILDIRIM H. Ç.
,
KUŞ F.
,
Erul E.
,
KERTMEN N.
,
DİZDAR Ö.
, et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded)
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
YILDIRIM H. Ç.
,
MUTLU E.
,
Chalabiyev E.
,
Ozen M.
,
KESKİNKILIÇ M.
,
ÖN S.
, et al.
BREAST
, cilt.66, ss.85-88, 2022 (SCI-Expanded)
Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
YILDIRIM H. Ç.
,
GÜVEN D. C.
,
AKTEPE O. H.
,
TABAN H.
,
YILMAZ F.
,
YAŞAR S.
, et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.17, 2022 (SCI-Expanded)
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
GÜVEN D. C.
,
ŞAHİN T. K.
,
Erul E.
,
ÇAKIR İ. Y.
,
ÜÇGÜL E.
,
YILDIRIM H. Ç.
, et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.15, 2022 (SCI-Expanded)
HER2-low breast cancer could be associated with an increased risk of brain metastasis
GÜVEN D. C.
,
KAYA M. B.
,
Fedai B.
,
ÖZDEN M.
,
YILDIRIM H. Ç.
,
KÖSEMEHMETOĞLU K.
, et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded)
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz E.
,
Ozbay M. F.
,
Caglayan D.
,
Yildirim A.
,
Erol C.
,
Yildirim H. C.
, et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.4, 2022 (SCI-Expanded)
The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
GÜVEN D. C.
,
YILDIRIM H. Ç.
,
ERUL E.
,
ŞAHİN T. K.
,
ÇAKIR İ. Y.
,
AKTEPE O. H.
, et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded)
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
Erol C.
,
Sakin A.
,
Başoglu T.
,
Özden E.
,
ÇABUK D.
,
Doğan M.
, et al.
Turkish Journal of Medical Sciences
, cilt.52, sa.4, ss.1022-1032, 2022 (SCI-Expanded)
A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer
GÜVEN D. C.
,
ŞAHİN T. K.
,
YILDIRIM H. Ç.
,
AKTEPE O. H.
,
DİZDAR Ö.
,
YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
, cilt.168, 2021 (SCI-Expanded)
The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy
AKTEPE O. H.
,
GÜVEN D. C.
,
ŞAHİN T. K.
,
YILDIRIM H. Ç.
,
ÇELİKTEN B.
,
Yeter H. H.
, et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
, cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded)
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C.
,
ŞAHİN T. K.
,
YILDIRIM H. Ç.
,
ÇEŞMECİ E.
,
Incesu F. G. G.
,
TAHILLIOĞLU Y.
, et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded)
Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C.
,
AKSUN M. S.
,
ŞAHİN T. K.
,
AKTEPE O. H.
,
YILDIRIM H. Ç.
,
TABAN H.
, et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded)
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report
GÜVEN D. C.
,
KILIÇKAP S.
,
YILDIRIM H. Ç.
,
Ceylan F.
,
BAŞ O.
,
DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded)
Impact of coronaphobia on treatment and follow-up compliance of cancer patients
Akagunduz B.
,
Ozer M.
,
Karacin C.
,
Atci M. M.
,
YILDIRIM H. Ç.
,
Unver E.
FUTURE ONCOLOGY
, cilt.17, ss.2621-2629, 2021 (SCI-Expanded)
Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group
Akagunduz B.
,
AKIN TELLİ T.
,
YILDIRIM H. Ç.
,
SEZGİN GÖKSU S.
,
DEMİR N.
,
Hafizoglu E.
, et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.31, sa.2, ss.92-98, 2021 (SCI-Expanded)
Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
GÜVEN D. C.
,
ŞAHİN T. K.
,
AKTEPE O. H.
,
YILDIRIM H. Ç.
,
AKSOY S.
,
KILIÇKAP S.
FRONTIERS IN ONCOLOGY
, cilt.10, 2020 (SCI-Expanded)
Diğer Dergilerde Yayınlanan Makaleler
Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç.
,
KUŞ F.
,
GÜVEN D. C.
,
Karaca E.
,
KAYGUSUZ Y.
,
DİZDAR Ö.
, et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature
KAHVECİOĞLU A.
,
Sari S. Y.
,
YILDIRIM H. Ç.
,
ARIK Z.
,
GÜLTEKİN M.
,
YILDIZ F.
Corrosion Science and Technology
, cilt.19, sa.3, ss.184-189, 2023 (ESCI)
Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer
YILDIRIM H. Ç.
,
ÜNER M.
,
Yildiran Özmen T.
,
Chalabiyev E.
,
GÜVEN D. C.
,
KUŞ F.
, et al.
Journal of Oncological Science
, cilt.9, sa.1, ss.33-37, 2023 (Scopus)
Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review
YILDIRIM H. Ç.
,
AKYILDIZ A.
,
Ismayilov R.
,
Demirok N.
,
BENLİ B. S.
,
Guven D. C.
, et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
, cilt.15, sa.4, ss.307-310, 2022 (ESCI)
Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
YILDIRIM H. Ç.
,
GÜVEN D. C.
,
AKTEPE O. H.
,
TABAN H.
,
YILMAZ F.
,
YAŞAR S.
, et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.1, ss.59-63, 2022 (ESCI)
Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy
YILDIRIM H. Ç.
,
Güven D. C.
,
Chalabiyev E.
,
Taban H.
,
YILMAZ F.
,
YAŞAR S.
, et al.
Journal of Oncological Science
, cilt.8, sa.3, ss.143-147, 2022 (Scopus)
Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma
AKTEPE O. H.
,
GÜNER G.
,
GÜVEN D. C.
,
TABAN H.
,
YILDIRIM H. Ç.
,
ŞAHİN T. K.
, et al.
TURKISH JOURNAL OF UROLOGY
, cilt.47, sa.2, ss.113-119, 2021 (ESCI)
Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery
Akagunduz B.
,
AKIN TELLİ T.
,
SEZGİN GÖKSU S.
,
YILDIRIM H. Ç.
,
Ozer M.
,
Aydin S. G.
, et al.
CUREUS
, cilt.13, sa.2, 2021 (ESCI)
Metrikler
Daha fazla metrik
Yayın
39
Atıf (WoS)
1
H-İndeks (WoS)
1
Atıf (Scopus)
79
H-İndeks (Scopus)
5
Açık Erişim
17
BM Sürdürülebilir Kalkınma Amaçları